Advancing the Evidence-Based Use of Antibody-Drug Conjugates Across the Breast Cancer Care Continuum
Antibody-drug conjugates are transforming the treatment of breast cancer across molecular subtypes, disease stages, and lines of therapy.
The Global Breast Cancer ADC Learning Hub provides oncology clinicians with timely, evidence-based education addressing HER2-directed and TROP2-directed ADCs, including emerging clinical trial data, treatment selection, sequencing, safety management, and practical application across diverse global practice settings.
This independent medical education initiative is designed for oncology clinicians and supported through educational grants from Daiichi Sankyo.
Explore the scientific advances, clinical evidence, and practice challenges shaping the use of antibody-drug conjugates worldwide.
Explore advances in the use of HER2-directed ADCs across HER2-positive, HER2-low, and HER2-ultralow breast cancer.
Key Areas:
Examine emerging evidence for TROP2-directed ADCs in triple-negative and hormone receptor-positive breast cancer.
Key Areas:
Key data highlighting the global disease burden, evolving treatment landscape, and educational needs surrounding ADC-based therapy.
2.4 Million
An estimated 2.4 million women were diagnosed with breast cancer worldwide in 2024. Breast cancer remains the most commonly diagnosed cancer among women, and the most common cause of cancer death in women.
World Health Organization. (2026, July 3). Breast cancer. World Health Organization
694,000
Breast cancer caused an estimated 694,000 deaths globally in 2024.
World Health Organization. (2026, July 3). Breast cancer. World Health Organization
1 in 20
Approximately 1 in 20 women worldwide will be diagnosed with breast cancer during their lifetime.
International Agency for Research on Cancer. (2025, February 24). Breast cancer cases and deaths are projected to rise globally. IARC
8.2 Million
An estimated 8.2 million women were living with breast cancer worldwide in 2024.
World Health Organization. (2026). Global breast cancer survival estimates. https://www.who.int/data/gho/data/themes/breast-cancer-survival
Explore curated ADC-focused activities featuring expert faculty, emerging clinical evidence, and practical guidance for breast cancer care.
The Global Breast Cancer ADC Learning Hub is guided by internationally recognized breast cancer experts who provide scientific oversight, regional perspectives, and practical guidance on the clinical use of ADCs.
0.75 Credits
4m
